VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-17

Reporting Person: Arbuckle Stuart A (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-17	Common Stock	F	6240	$211.75	Disposed	55460	Direct
2021-02-18	Common Stock	S	1022	$210.05	Disposed	54438	Direct
2021-02-18	Common Stock	S	3940	$211.77	Disposed	50498	Direct
2021-02-18	Common Stock	S	2763	$212.49	Disposed	47735	Direct
2021-02-18	Common Stock	S	100	$213.26	Disposed	47635	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $210.05 (range $209.63 to $210.52).

F3: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $211.77 (range $211.15 to $212.14).

F5: Open market sales reported on this line occurred at a weighted average price of $212.49 (range $212.15 to $213.04).

F6: Open market sales reported on this line occurred at a weighted average price of $213.26 (range $213.23 to $213.29).